Transcenta Holding Limited (HKG: 6628) announced that its partner Inhibrx Biosciences, Inc. (NASDAQ: INBX) has reported favorable topline data from the ChonDRAgon phase III registrational study (n = 206) of ozekibart (INBRX‑109) versus placebo in patients with advanced or metastatic, unresectable chondrosarcoma.
Based on these outcomes, Inhibrx intends to file for U.S. regulatory approval by the end of June 2026.
Study and Therapeutic Highlights
| Item | Detail |
|---|---|
| Drug | Ozekibart (INBRX‑109) – a precision‑engineered, tetravalent death receptor 5 (DR5) agonist antibody |
| Mechanism | Engages tumor‑biased apoptosis via DR5 activation |
| Trial | ChonDRAgon – randomized, placebo‑controlled Phase III (206 patients) |
| Endpoints | Not yet disclosed; topline data indicate statistically significant benefit |
| Regulatory Status | Fast Track (FDA, Jan 2021) & Orphan Drug (FDA, Nov 2021) designations for metastatic/unresectable conventional chondrosarcoma |
Licensing and Commercial Rights
Transcenta holds exclusive rights to develop and commercialize ozekibart in Mainland China, Hong Kong SAR, Macau SAR, and Taiwan under a license agreement with HJB (Hangzhou) Co., Ltd, a wholly‑owned subsidiary of Transcenta. The partnership leverages Transcenta’s regional pipeline expertise and Inhibrx’s late‑stage development capabilities.
Market Implications
- Chondrosarcoma remains a rare, high‑need indication with limited approved therapies.
- Ozekibart’s positive data and dual regulatory designations suggest a strong commercial trajectory if U.S. approval is secured.
- The licensing structure positions Transcenta to monetize early and mid‑stage pipeline assets while Inhibrx focuses on U.S. regulatory pathways.-Fineline Info & Tech
